Reviewing ProPhase Labs (NASDAQ:PRPH) & Medicure (OTCMKTS:MCUJF)

ProPhase Labs (NASDAQ:PRPH) and Medicure (OTCMKTS:MCUJF) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Valuation and Earnings

This table compares ProPhase Labs and Medicure”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06 million	0.10	-$53.36 million	($3.90)	-0.02
Medicure	$15.99 million	0.53	-$760,000.00	($0.24)	-3.35

Medicure has higher revenue and earnings than ProPhase Labs. Medicure is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ProPhase Labs and Medicure, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1	0	0	0	1.00
Medicure	0	0	0	0	0.00

Volatility & Risk

ProPhase Labs has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500. Comparatively, Medicure has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Profitability

This table compares ProPhase Labs and Medicure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Medicure	-13.10%	-17.91%	-11.95%

Insider and Institutional Ownership

9.4% of ProPhase Labs shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 12.9% of Medicure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Medicure beats ProPhase Labs on 9 of the 12 factors compared between the two stocks.

About ProPhase Labs

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

About Medicure

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.